Evercyte and VTU Launch Recombinant Media Supplement

May 24, 2016
Pharmaceutical Technology Editors

The companies have launched VEGF 165, their first joint product for cell culture applications.

Evercyte GMbH and VTU Technology have entered into a collaboration agreement on the development of recombinant media supplements for cell culture applications and launched their first conjointly developed recombinant product, according to a May 24, 2016 press announcement. Vascular Endothelial Growth Factor 165 (VEGF 165), the company’s newly released product, is a growth factor with physiological and clinical relevance used in diverse biological in-vitro tests.

The Evercyte and VTU collaboration will allow the companies to develop recombinant media supplements, including growth factors and cytokines. Recombinant products will be produced by VTU based on its proprietary Pichia technology, facilitating the manufacturing of media supplements.

Source: Evercyte

 

Related Content:

PharmTech News | Supplier News